Cough syrup contaminated with DEG has caused ARI and the death of many children in The Gambia.

Published Date: 06 Mar 2023

USA: The syrup drug Diethylene glycol (DEG), a drug commonly used to prevent infections, is the cause of kidney disease...

Read Full News

Latest News

Personalizing IgA Nephropathy Care Conversations, With Gaia Coppock, MD Gaia Coppock, MD

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

Mistaken for a UTI: Diagnosing IgA Nephropathy, With Gaia Coppock, MD Gaia Coppock, MD

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

6 Nephrology Headlines You Missed in September 2026

6 Nephrology Headlines You Missed in September 2026

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

5 Nephrology Headlines You Missed in August 2026 Alex Hillenbrand

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

First New Drug Approved for Idiopathic Nephrotic Syndrome in 70 Years

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Todays Updates

TRPA1 Antagonist Shows Delayed but Meaningful Effect on IPF Cough Marlies Wijsenbeen, MD, PhD

Marlies Wijsenbeek, MD, PhD, of Erasmus MC discusses BI 1839100, a TRPA1 antagonist, which missed its week-4 endpoint in a phase 2/2b trial.

Mepolizumab Reduces Systemic Corticosteroid Exposure in Eosinophilic COPD Chelsie Derman

In pooled phase 3 data, mepolizumab lowered mean yearly systemic corticosteroid exposure by 178.97 mg in patients with a BEC of ≥150 cells/µL.

ASPEN: Sputum Color Associated With Bronchiectasis Disease Activity Victoria Johnson

A post hoc analysis linked more purulent patient-reported sputum to higher neutrophil elastase activity and greater bronchiectasis disease activity.

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

Sphingolipid Profiles May Distinguish IPF from Fibrotic HP

CHEST 2026: Day 1 Recap — 5 Headlines to Know

CHEST 2026: Day 1 Recap — 5 Headlines to Know

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

PAH Combination Therapy and Escalation: Clinical Forum Perspectives

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

APP Experts Discuss Earlier Biologic Use in Asthma and COPD

Latest News

Why patients with IgA nephropathy want to understand their disease, not just follow instructions.

A survey of patients with IgA nephropathy shows how nonspecific symptoms and long referral waits delay diagnosis by up to two years.

6 Nephrology Headlines You Missed in September 2026

Lessons From 10,000 Organ Transplants, With Ari Cohen, MD

A joint ESC/ERA guideline on universal CKD screening headlines August 2026's nephrology news, alongside new finerenone and sibeprenlimab trial data.

— Anti-CD20 agent obinutuzumab (Gazyva) gets green light for patients as young as 2 years

News All Time

Closing the Gaps in CKD Screening, Transplant Access, and Education for Incarcerated Patients Laura Maursetter, MD

Laura J. Maursetter, MD, discusses the case for standardized kidney screening protocols, transplant access, and medical education reform for the correctional population.

Why IgA Nephropathy Risk Stratification Still Falls Short Ali Mehdi, MD, MEd

Cleveland Clinic's Ali Mehdi, MD, MEd, on the limits of current IgA nephropathy risk tools and where phenotyping could take treatment next.

Kidney Organoids Show Persistent AKI Injury, With Alexander Combes, PhD Alexander Combes, PhD

Human kidney organoids reveal why proximal tubule cells resist full recovery after AKI, aiding drug screening research.

For Incarcerated Patients, Kidney Care Can't Wait, With Laura Maursetter, MD Laura Maursetter, MD

A nephrologist outlines gaps in CKD tracking, medication access, and transplant standards across the carceral health system.

Pacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial Abigail Brooks, MA

The phase 2 TRANQUILITY trial found the IL-6 antibody pacibekitug produced sustained, dose-dependent reductions in hs-CRP in patients with chronic kidney disease.

New ESC, ERA Guideline Calls for Universal CKD Screening in Cardiovascular Disease Abigail Brooks, MA

The ESC and ERA issued their first joint guideline recommending universal CKD screening and expanded use of risk-modifying therapies in patients with cardiovascular disease.

Diagnosis to Data: What Patient Experience Adds to IgAN Research Bryon Wade

A principal healthcare consultant and study co-author shares his own decade-long path to an IgA nephropathy diagnosis and transplant.

Atacicept Cuts IgAN Progression Risk 76% in ORIGIN 3 Final Data Alex Hillenbrand

Atacicept also stabilized eGFR and matched placebo on safety, with a full FDA approval filing planned for Q4 2026.

FAQ: Understanding New ESC/ERA Guideline on Cardiovascular Disease and Chronic Kidney Disease Patrick Campbell

ESC and ERA issue the first dedicated guideline on managing cardiovascular disease alongside chronic kidney disease, via a “STAMP on CKD” framework.

Kidney Organoids May Speed AKI Drug Screening, With Alexander Combes, PhD Alexander Combes, PhD

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

Inaxaplin Cuts Proteinuria in Broader APOL1 Kidney Disease Population Alex Hillenbrand

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care George Vasquez-Rios, MD

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Vicadrostat EASi-KIDNEY Trial Discontinued for Lack of Benefit in CKD Abigail Brooks, MA

Boehringer Ingelheim halted EASi-KIDNEY after a DMC found data did not support a meaningful clinical benefit on the trial's primary endpoint.

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

The HCPFive: Top News for Healthcare Providers from the Week of 09/20

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH

Recommended News For You

What Role Should Genomic Classifier Testing Play in Prostate Cancer?

AI model combines clinical and magnetic resonance data to improve prediction of breast cancer recurrence

Telemedicine Not Reaching Rural Psychiatric Patients

FDA Expands Durvalumab Label to Operable Lung Cancer

Significant worldwide disparities seen in availability and timeliness of new cancer drugs

Talquetamab Regimens Boost Survival in Multiple Myeloma

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

Recommended Articles For You

AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies 

Modern Strategies in Hematology for Specialists 

Personalized Hematology Through Patient-Specific Cellular Profiles 

Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars

2.

The Growing Role of AI in Cancer Treatment

3.

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

4.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

5.

Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training

1.

Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies

2.

Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

3.

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025

4.

Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization

5.

Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II

2.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV

3.

Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment

4.

How Multidisciplinary Teams Support Modern Cancer Care

5.

Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot